Evaluate Risk/Benefit of Nab Paclitaxel in Combination With Gemcitabine and Carboplatin Compared to Gemcitabine and Carboplatin in Triple Negative Metastatic Breast Cancer (or Metastatic Triple Negative Breast Cancer) — tnAcity

Breast Cancer Clinical Trial

Official title:
A Phase 2/3, Multi-Center, Open-Label, Randomized Study of Weekly Nab®-Paclitaxel in Combination With Gemcitabine or Carboplatin, Compared to Gemcitabine/Carboplatin, as First Line Treatment in Subjects With ER, PgR, and HER2 Negative (Triple Negative) Metastatic Breast Cancer

NCT number	NCT01881230
Study type	Interventional
Source	Celgene
Contact
Status	Completed
Phase	Phase 2/Phase 3
Start date	September 26, 2013
Completion date	October 28, 2016

View Details

Status Completed

Clinical Trial Summary

The purpose of this study is to compare the safety and efficacy of nab-paclitaxel in combination with either gemcitabine or carboplatin to the combination of gemcitabine and carboplatin as first line treatment in female subjects with triple negative metastatic breast cancer (TNMBC) or metastatic triple negative breast cancer.

Clinical Trial Description

ABI-007-MBC- 001 is a Phase 2/3, multicenter, open-label, randomized, study that will compare the safety and efficacy of weekly nab-paclitaxel in combination with gemcitabine or carboplatin to the combination of gemcitabine and carboplatin as first line therapy in female subjects with Estrogen Receptor (ER), Progesterone Receptor (PgR), and human epidermal growth factor receptor 2 (HER2) negative (triple negative) metastatic breast cancer (TNMBC) or metastatic triple negative breast cancer. In the phase 2 portion of the study, the combinations of nab-paclitaxel plus gemcitabine and nab-paclitaxel plus carboplatin will be evaluated, and a comparator arm of gemcitabine combined with carboplatin will be used. In the phase 3 portion of the study, the selected nab-paclitaxel combination treatment will be compared to gemcitabine combined with carboplatin to evaluate progression free survival, safety and tolerability, overall survival, disease control rate and duration of response in women with metastatic triple negative breast cancer.

Due to changes in the treatment landscape since the initiation of this trial, the decision was made not to proceed to the Phase 3 portion of the study.

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT01472094` - Clinical and Biological Predictors of Chemotherapy Toxicity in Older Adults	N/A
Completed	`NCT00341939` - Retrospective Analysis of a Drug-Metabolizing Genotype in Cancer Patients and Correlation With Pharmacokinetic and Pharmacodynamics Data	N/A
Recruiting	`NCT01857193` - Phase Ib Trial of LEE011 With Everolimus (RAD001) and Exemestane in the Treatment of Hormone Receptor Positive HER2 Negative Advanced Breast Cancer	Phase 1
Active, not recruiting	`NCT02139358` - Phase I/IIa Trial of Gemcitabine Plus Trastuzumab and Pertuzumab in Previously Treated Metastatic HER2+ Breast Cancer	Phase 1/Phase 2
Not yet recruiting	`NCT03210311` - Pre-existing Factors, Early Detection and Early Treatment of Breast Cancer Related Lymphedema	Phase 3
Terminated	`NCT01649258` - Fosaprepitant Dimeglumine and Granisetron Transdermal System in Preventing Nausea and Vomiting in Patients With Breast Cancer Undergoing Chemotherapy	N/A
Not yet recruiting	`NCT02955394` - Preoperative Fulvestrant With or Without Enzalutamide in ER+/Her2- Breast Cancer	Phase 2
Recruiting	`NCT01992432` - Brain Functional MRI in Older Women With Breast Cancer (Brain fMRI-BC)	N/A
Completed	`NCT01943500` - Collection of Blood Specimens for Circulating Tumor Cell Analysis	N/A
Active, not recruiting	`NCT02371174` - Post-Marketing Surveillance Study of Eribulin on the Status and Factors for the Development of Peripheral Neuropathy in Japan.	N/A
Recruiting	`NCT02125019` - Longitudinal Evaluation of Taxane Induced Neuropathy in Early Stage Breast Cancer	N/A
Recruiting	`NCT01967823` - T Cell Receptor Immunotherapy Targeting NY-ESO-1 for Patients With NY-ESO-1 Expressing Cancer	Phase 2
Recruiting	`NCT02739425` - The Efficacy of Sentimag in Detection of Sentinel Node Biopsy	N/A
Not yet recruiting	`NCT02767661` - Metronomic Capecitabine Plus Aromatase Inhibitor for First Line Treatment in HR(+), Her2(-) Metastatic Breast Cancer	Phase 3
Not yet recruiting	`NCT03197805` - Assessment of the Impact of RNA Genomic Profile on Treatment Decision-making in HER2 Equivocal Breast Cancer Patients	N/A
Not yet recruiting	`NCT03176888` - Health Benefits of HIT for Breast Cancer Patients	N/A
Not yet recruiting	`NCT03159598` - Drain-Less Abdominally Based Breast Reconstruction Using Lysine-Derived Urethane Adhesive	N/A
Not yet recruiting	`NCT00960544` - Correlation of Genomic Variation in Enzymes Responsible for Metabolism of Capecitabine With Drug Metabolism	Phase 2
Not yet recruiting	`NCT02943265` - Care Coordination for Complex Cancer Survivors in an Integrated Safety Net System	N/A
Not yet recruiting	`NCT03122444` - Imipramine on Triple Negative Breast Cancer	N/A